Pixium Sees Way Forward For Its Vision-Restoring Implants In A Tough Market
The company has just two quarters’ of cash remaining, but has also achieved major milestones towards the development and commercialization of its implant that hopes to restore vision in patients with age-related macular degeneration.
You may also be interested in...
Leaders of burgeoning ophthalmology companies pitched innovations for treating glaucoma, macular degeneration and corneal blindness to potential investors and partners at the LSI Emerging Medtech Summit in Dana Point, CA. Here’s what Medtech Insight heard and learned in on-site interviews with chief executives.
Investor Eye: Sofinnova Speaks On Deal Execution, Managing Expertise And what’s In Store For The Future
Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.
Medtech Insight spoke to the CEOs of Blackrock Neurotech and Pixium Vision to find out how their devices can restore lost neurological function and how devices that interface with the brain may shape the future of medicine.